Volume 11, Issue 6, Pages 735-739 (December 2012) The Global Cell Therapy Industry Continues to Rise during the Second and Third Quarters of 2012  Chris Mason, Mark J. McCall, Emily J. Culme-Seymour, Shalini Suthasan, Simon Edwards-Parton, Gregory A. Bonfiglio, Brock C. Reeve  Cell Stem Cell  Volume 11, Issue 6, Pages 735-739 (December 2012) DOI: 10.1016/j.stem.2012.11.013 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 Share Price Movement for the First Three Quarters of 2012 Compared to the Close of Q4 2011 The share price for the end of 2011 was taken as the base point, and the percentage change from this for each quarter for individual companies has been plotted. The graph order of the companies was then established in terms of their overall change to the end of Q3 2012, with those that had the biggest Q4 2011 to Q3 2012 positive change on the left. Splits and reverse splits have been factored in. See also Table S1 for the underlying stock price information used to generate this graph. Cell Stem Cell 2012 11, 735-739DOI: (10.1016/j.stem.2012.11.013) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 2 Clinical Trial Data for Ongoing Clinical Trials being Conducted by Publicly Listed Cell Therapy Companies at the Close of Q3 2012 Data was solely sourced from http://www.clinicaltrials.gov and only includes the “ongoing” cell therapy trials for the individual companies (i.e., they do not include their other non-cell-based activities) and for where the company acted as a “sponsor” and/or “collaborator.” Multinational pharma, biotech, and medical device companies are excluded. See Table S2 for the underlying data used to generate this graph. Cell Stem Cell 2012 11, 735-739DOI: (10.1016/j.stem.2012.11.013) Copyright © 2012 Elsevier Inc. Terms and Conditions